To further investigate the clinical significance of the markedly higher levels of circulating cell death biomarkers in HBV-ACLF patients, we performed regression analyses to compare levels of cell death biomarkers with well-established liver injury markers including ALT and AST, with HBV-DNA load and additionally with albumin, TB and INR, since decreased albumin, hyperbilirubinemia and coagulopathy are the hallmarks of liver manifestation of ACLF patients. This evidence concerns the gene ALB and blood coagulation disease.